The pharmacology of antithrombotic and antiplatelet agents

Anesthesiology Clinics of North America

Volumn 17, Issue 4, 1999, Pages 749-786

  Abu Hajir, M ^a   Mazzeo, A J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARDEPARIN; CLOPIDOGREL; COUMARIN DERIVATIVE; DALTEPARIN; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPARINOID; HIRUDIN; KETANSERIN; LAMIFIBAN; LEPIRUDIN; ORG 101509; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDINE DERIVATIVE; R HIRUDIN; RP 54563; SARPOGRELATE; SEROTONIN ANTAGONIST; THROMBIN INHIBITOR; TICLOPIDINE; TINZAPARIN; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XEMILOFIBAN;

BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0032759889     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(05)70132-2     Document Type: Article

References (94)

1. M. Abu-Hajir R.S. Kuhlmann T.R. Wigton Low-Molecular Weight Heparin (LMWH) in pregnancy: Role of anti-Xa monitoring Thromb Haemost 82 1999 846
2. G.P. Aithal C.P. Day P.J.L. Kesteven Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 1999 717
3. Anonymous CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group Lancet 349 1997 1641
4. Anonymous Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration [published erratum appears in BMJ 1994, Jun 11; 308(6943):1540] BMJ 308 1994 81
5. Anonymous Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrelin therapy N Engl J Med 339 1998 436
6. Anonymous The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group Lancet 349 1997 1569
7. Anonymous Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators N Engl J Med 336 1997 1689
8. Anonymous Prevention of atherosclerotic complications: Controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group [published erratum appears in BMJ 1989, Mar 11;298(6674):644] BMJ 298 1989 424
9. Anonymous A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet 348 1996 1329
10. Anonymous Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT) Circulation 89 1994 588
11. Anonymous Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group Lancet 336 1990 827
12. Anonymous Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group Lancet 338 1991 1345
13. Anonymous Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework Lancet 351 1998 233
14. Anonymous Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation N Engl J Med 330 1994 956
15. J.S. Barrett G. Murphy K. Peerlinck Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist in healthy men Clin Pharmacol Ther 56 1994 377
16. C.L. Bennett P.D. Weinberg K. Rozenberg-Ben-Dror Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases Ann Intern Med 128 1998 541
17. I. Bjork U. Lindahl Mechanism of the anticoagulant action of heparin Mol Cell Biochem 48 1982 161
18. B. Boneu G. Destelle Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients Thromb Haemost 76 1996 939
19. D. Brieger J. Dawes Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins Thromb Haemost 77 1997 317
20. J.K. Burgess B.H. Chong The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls Eur J Haematol 58 1997 279
21. J.A. Cairns P. Theroux H.D. Lewis Jr Antithrombotic agents in coronary artery disease Chest 114 suppl 1998 611
22. M. Cohen C. Demers E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group N Engl J Med 337 1997 447
23. B.S. Coller GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab Thromb Haemost 78 1997 730
24. B.S. Coller Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics J Clin Invest 100 suppl 1997 57
25. B.S. Coller K. Anderson H.F. Weisman New antiplatelet agents: Platelet GPIIb/IIIa antagonists Thromb Haemost 74 1995 302
26. A.J. Coukell A. Markham Clopidogrel Drugs 54 1997 745
27. M.A. Crowther D. Donovan L. Harrison Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin Thromb Haemost 79 1998 1116
28. U.R. Desai M. Petitou I. Bjork Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin J Biol Chem 273 1998 7478
29. G. Di Minno A.M. Cerbone P.L. Mattioli Functionally thrombasthenic state in normal platelets following the administration of ticlopidine J Clin Invest 75 1985 328
30. H.C. Diener L. Cunha C. Forbes European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke J Neurol Sci 143 1996 1
31. P.P. Dobesh K.A. Latham Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors Pharmacotherapy 18 1998 663
32. M.S. Egbertson C.T. Chang M.E. Duggan Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp J Med Chem 37 1994 2537
33. B.I. Eriksson P. Wille-Jorgensen P. Kalebo A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement N Engl J Med 337 1997 1329
34. J.J. Ferguson R. Fox Meeting highlights. The 69th Scientific Sessions of the American Heart Association in New Orleans, LA, November 10–13, 1996 [news] Circulation 95 1997 761
35. C.W. Fetrow T. Overlock L. Leff Antagonism of warfarin-induced hypoprothrombinemia with use of low-dose subcutaneous vitamin K1 J Clin Pharmacol 37 1997 751
36. J.N. Fiessinger M. Schafer Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study Lancet 335 1990 555
37. G.A. FitzGerald Dipyridamole N Engl J Med 316 1987 1247
38. J.E. Freedman J.H. Farhat J. Loscalzo Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism Circulation 94 1996 2434
39. M. Gent J.A. Blakely J.D. Easton The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke Lancet 1 1989 1215
40. A. Greinacher H. Volpel U. Janssens Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study Circulation 99 1999 73
41. T. Hamamoto W. Kisiel The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor Blood Coagul Fibrinolysis 7 1996 470
42. J.B. Hansen P.M. Sandset K.R. Huseby Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action Br J Haematol 101 1998 638
43. J.B. Hansen P.M. Sandset K.R. Huseby Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man Thromb Haemost 76 1996 703
44. L. Hansson A. Zanchetti S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1998 1755
45. R.A. Harrington N.S. Kleiman K. Kottke-Marchant Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention Am J Cardiol 76 1995 1222
46. W.K. Hass J.D. Easton H.P. Adams Jr A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N Engl J Med 321 1989 501
47. C.H. Hennekens M.L. Dyken V. Fuster Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association Circulation 96 1997 2751
48. J. Hirsh J.E. Dalen D.R. Anderson Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 114 suppl 1998 445
49. Z.F. Huang D. Higuchi N. Lasky Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice Blood 90 1997 944
50. S. Juul-Moller N. Edvardsson B. Jahnmatz Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group Lancet 340 1992 1421
51. W. Klein A. Buchwald S.E. Hillis Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC) [see comments section] [published erratum appears in Circulation 1998, Feb 3;97(4):413] Circulation 96 1997 61
52. K.L. Kunze L.C. Wienkers K.E. Thummel Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies Drug Metab Dispos 24 1996 414
53. E.J. Langford R.J. Wainwright J.F. Martin Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors Arterioscler Thromb Vasc Biol 16 1996 51
54. A. Laupacis G. Albers J. Dalen Antithrombotic therapy in atrial fibrillation Chest 114 suppl 1998 579
55. J. Lefkovits E.F. Plow E.J. Topol Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine N Engl J Med 332 1995 1553
56. B. Lindblad N.H. Persson R. Takolander Does low-dose acetylsalicylic acid prevent stroke after carotid surgery: A double-blind, placebo-controlled randomized trial Stroke 24 1993 1125
57. G.Y. Lip G.D. Lowe ABC of atrial fibrillation: Antithrombotic treatment for atrial fibrillation BMJ (Clinical Research Ed) 312 1996 45
58. H.N. Magnani Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993, Dec 20;70(6):1072] Thromb Haemost 70 1993 554
59. F. Manzato A. Mengoni A. Grilenzoni Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: Implications for therapeutic monitoring Clin Chem Lab Med 36 1998 975
60. M.A. Mascelli E.T. Lance L. Damaraju Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade Circulation 97 1998 1680
61. H. Menger A.E. Lin H.V. Toriello Vitamin K deficiency embryopathy: A phenocopy of the warfarin embryopathy due to a disorder of embryonic vitamin K metabolism Am J Med Genet 72 1997 129
62. R.S. More A. Chauhan Antiplatelet rather than anticoagulant therapy with coronary stenting Lancet 349 1997 146
63. R.L. Mueller S. Scheidt History of drugs for thrombotic disease: Discovery, development, and directions for the future Circulation 89 1994 432
64. J.M. Muir J. Hirsh J.I. Weitz A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats Blood 89 1997 3236
65. S. Noble K.L. Goa Ticlopidine: A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke [published erratum appears in Drugs Aging 1996, Jun;8(6):444] Drugs Aging 8 1996 214
66. S. Noble D.H. Peters K.L. Goa Enoxaparin: A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease Drugs 49 1995 388
67. S.T. Olson I. Bjork R. Sheffer Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: Resolution of the antithrombin conformational change contribution to heparin rate enhancement J Biol Chem 267 1992 12528
68. C. Patrono Aspirin as an antiplatelet drug N Engl J Med 330 1994 1287
69. C. Patrono Platelet-active drugs the relationships among dose, effectiveness, and side effects Chest 114 suppl 1998 470
70. C. Patrono G.A. FitzGerald Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease Arterioscler Thromb Vasc Biol 17 1997 2309
71. C. Patrono G.J. Roth Aspirin in ischemic cerebrovascular disease How strong is the case for a different dosing regimen? Stroke 27 1996 756
72. A.K. Pedersen G.A. FitzGerald Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclooxygenase N Engl J Med 311 1984 1206
73. K. Peerlinck I. De Lepeleire M. Goldberg MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man Circulation 88 1993 1512
74. J.J. Popma J. Weitz J.A. Bittl Antithrombotic therapy in patients undergoing coronary angioplasty Chest 114 suppl 1998 728
75. B. Potzsch K. Madlener C. Seelig Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass—Assessment of the whole blood ecarin clotting time Thromb Haemost 77 1997 920
76. R.A. Raschke B. Gollihare J.C. Peirce The effectiveness of implementing the weight-based heparin nomogram as a practice guideline Arch Intern Med 156 1996 1645
77. F.C. Riess B. Potzsch I. Behr Recombinant hirudin as an anticoagulant during cardiac operations: Experiments in a pig model Eur J Cardiothorac Surg 11 1997 739
78. B. Roth M. Ekelund B.G. Fan Effects of heparin and low molecular weight heparin on lipid transport during parenteral feeding in the rat Acta Anaesthesiol Scand 40 1996 102
79. R.M. Scarborough M.A. Naughton W. Teng Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa J Biol Chem 268 1993 1066
80. A.I. Schafer Antiplatelet therapy Am J Med 101 1996 199
81. A. Schomig F.J. Neumann A. Kastrati A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med 334 1996 1084
82. K. Schror Antiplatelet drugs: A comparative review Drugs 50 1995 7
83. P.J. Sharis C.P. Cannon J. Loscalzo The antiplatelet effects of ticlopidine and clopidogrel Ann Intern Med 129 1998 394
84. D.J. Steward R.L. Haining K.R. Henne Genetic association between sensitivity to warfarin and expression of CYP2C9*3 Pharmacogenetics 7 1997 361
85. H. Takahashi T. Kashima Y. Nomizo Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes Clin Pharmacol Ther 63 1998 519
86. J.E. Tcheng S.G. Ellis B.S. George Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty Circulation 90 1994 1757
87. H.H. van Barlingen A. van Beek D.W. Erkelens Danaparoid: An antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans J Intern Med 242 1997 125
88. M. Verstraete Heparin and thrombosis: A seventy year long story Haemostasis 20 1990 4
89. T.E. Warkentin B.H. Chong A. Greinacher Heparin-induced thrombocytopenia: Towards consensus Thromb Haemost 79 1998 1
90. T.E. Warkentin M.N. Levine J. Hirsh Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330
91. J.I. Weitz J. Hirsh New antithrombotic agents Chest 114 suppl 1998 715
92. D. Wellesley I. Moore M. Heard Two cases of warfarin embryopathy: A re-emergence of this condition? Br J Obstet Gynaecol 105 1998 805
93. H.A. Wynne F. Kamali C. Edwards Effect of ageing upon warfarin dose requirements: A longitudinal study Age Ageing 25 1996 429
94. E. Young P. Wells S. Holloway Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin Thromb Haemost 71 1994 300